Article

SARS-CoV-2 infection enhancement by Amphotericin B: Implications for disease management

2024-11-07

Abstract excerpt

Severe coronavirus disease 2019 (COVID-19) patients who require hospitalisation are at high risk of invasive pulmonary mucormycosis. Amphotericin B (AmB), which is the first line therapy for invasive pulmonary mucormycosis, has been shown to promote or inhibit replication of a spectrum of viruses. In this study, we first predicted that AmB and Nystatin had strong interactions with severe acute respiratory syndrome...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4bad703b-c466-5821-97a7-e5780f60e1a7
DOI: 10.1101/2024.11.07.622419

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

SARS-CoV-2 infection enhancement by Amphotericin B: Implications for disease managementDOI 10.1101/2024.11.07.622419Read

Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA ReplicationSemantic proximity Read

Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection?Semantic proximity Read

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitroSemantic proximity Read

The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replicationSemantic proximity Read

Non-invasive aspergillosis following COVID-19 exacerbates the severity of SARS-CoV-2 infectionSemantic proximity Read

Druggable targets and therapeutic development for COVID-19Semantic proximity Read

Transcriptomic Analysis of the Peripheral Immune Cell of SARS-CoV-2 Infected Patients for Bridging the Genotype-Phenotype Gap and Drug Prediction: A Precision Medicine ApproachSemantic proximity Read